King Pharmaceuticals Appoints John J. Howarth Vice President Investor Relations

BRISTOL, Tenn.--(Business Wire)--
King Pharmaceuticals, Inc. (NYSE:KG) today announced the appointment of John J.
Howarth to Vice President, Investor Relations. Mr. Howarth joins King with over
25 years of experience in the healthcare industry, including executive positions
at specialty pharmaceutical companies, as well as large global pharmaceutical
companies.

"We are extremely pleased to add Jack to our team," stated Joseph Squicciarino,
King`s Chief Financial Officer. "We are confident that Jack`s expertise in
investor relations and extensive knowledge of the specialty pharmaceutical
industry will complement our senior management team as we focus on executing our
long-term growth strategy."

Most recently, Mr. Howarth was Vice President, Investor Relations at Alpharma
Inc., which King acquired in December 2008. Previously, he served in similar
roles at MedPointe Pharmaceuticals and Kos Pharmaceuticals. Mr. Howarth received
his BS degree in accounting from Boston College and an MBA in finance from Seton
Hall University.

About King Pharmaceuticals, Inc.

King, headquartered in Bristol, Tennessee, is a vertically integrated branded
pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on
opportunities in the pharmaceutical industry through the development, including
through in-licensing arrangements and acquisitions, of novel branded
prescription pharmaceutical products and technologies that complement the
Company`s focus in specialty-driven markets, particularly neuroscience and
hospital. King is also a leader in the development, registration, manufacture
and marketing of pharmaceutical products for food producing animals.

King Pharmaceuticals, Inc.
Jack Howarth, 908-429-8350
Vice President, Investor Relations

Copyright Business Wire 2009